Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02931838 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Phase 2 study of Psoriasis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 268
- Enrollment target
- 20
- Study locations
NCT02931838 is a Phase 2 study of Psoriasis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 268 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT02931838, a Phase 2 study of Psoriasis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 268 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
Conditions Studied
Interventions
- DRUG BMS-986165
- DRUG Placebo for BMS-986165
Study Locations (20)
North Carolina
- Piedmont Plastic Surgery & Dermatology - Charlotte/Blakeney Location - Charlotte
- PMG Research of Rocky Mount, LLC - Rocky Mount
- PMG Research of Wilmington, PLC - Wilmington
California
- University of California Irvine - Irvine
- University of California San Diego - San Diego
Illinois
- PMG Research of Christie Clinic, LLC - Champaign
- NorthShore University Health System - Skokie
Tennessee
- Rivergate Dermatology Clinical Research Center, Pllc - Goodlettsville
- Local Institution - Knoxville
Florida
- Renstar Medical Research - Ocala
Georgia
- Dermatologic Surgery Specialists, PC - Macon
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
New Hampshire
- Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2017-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02931838
The ClinicalTrials.gov registry entry for NCT02931838 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 268 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (45% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which BMS-986165 is the first listed.
NCT02931838 reports 20 study locations spanning 15 distinct geographic areas - top geographies include North Carolina, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT02931838 about?
NCT02931838 is a clinical study titled "Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis". A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
What is the current status of trial NCT02931838?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 268 participants. The study started on 2016-11-15. Estimated completion is 2017-11-16.
What conditions does trial NCT02931838 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02931838?
The interventions under investigation include: BMS-986165 (DRUG), Placebo for BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT02931838?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02931838 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.